Skip to main content
. 2024 Sep 16;42(36):4271–4281. doi: 10.1200/JCO-24-01798

FIG 3.

FIG 3.

Additional secondary time-to-event end points (full analysis set). (A) Time to metastatic castration-resistant prostate cancer and (B) time to PSA progression. Hazard ratios and 95% CIs were calculated using the Cox regression model stratified by the presence of visceral metastases and prior therapy. ADT, androgen-deprivation therapy; NR, not reached; PSA, prostate-specific antigen.